Sarepta Fallout Continues with EU’s Negative Opinion of Elevidys in Ambulatory Patients

By /

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne muscular dystrophy.

Scroll to Top